Rigosertib - Onconova Therapeutics

Drug Profile

Rigosertib - Onconova Therapeutics

Alternative Names: Estybon; Novonex; ON-01910; ON-01910-sodium; ON-01910.Na; Rigosertib sodium; SyB 1101; SyB C-1101; SyB L-1101

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onconova Therapeutics
  • Developer M. D. Anderson Cancer Center; Onconova Therapeutics; SymBio Pharmaceuticals
  • Class Amino acids; Antineoplastics; Small molecules; Sulfones
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Myelodysplastic syndromes
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia; Myelofibrosis; Solid tumours
  • Phase I Head and neck cancer
  • No development reported Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Ovarian cancer; Pancreatic cancer
  • Discontinued Squamous cell cancer

Most Recent Events

  • 15 Nov 2017 Efficacy and adverse events data from a phase I/II trial in myelodysplastic syndromes, acute myeloid leukaemia or chronic myelomonocytic leukaemia released by Onconova Therapeutics
  • 09 Nov 2017 Onconova, in collaboration with the National Cancer Institute, plans a clinical trial for Myelodysplastic syndromes (Paediatric RASopathies) in USA in 2018
  • 09 Nov 2017 Onconova Therapeutics plans to initiate a Special Protocol Assessment process with the US FDA for a pivotal phase III trial in Myelodysplastic syndromes (First-line therapy, Combination therapy) in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top